ELITE Cost, Cost-Effectiveness, and Health-Economic Implications

At a glance

| Field | Detail | |---|---| | Trial | ELITE (Early versus Late Intervention Trial with Estradiol) | | N | 643 postmenopausal women | | Intervention | Oral 17β-estradiol 1 mg/day plus progesterone vaginal gel (for women with a uterus) | | Comparator | Matched placebo | | Duration | Median 5 years | | Primary Endpoint | Rate of change in carotid intima-media thickness (CIMT) by time since menopause | | Key Result | Early-initiation group (<6 years post-menopause): significantly slower CIMT progression vs placebo (p = 0.008); late-initiation group (≥10 years): no significant difference | | Primary Source | Hodis et al., NEJM 2016 |

Why Economics Matter Here

The ELITE primary results landed in a coverage environment already shaped by the Women's Health Initiative's cardiovascular safety signals from 2002. Payers who restricted hormone therapy reimbursement after WHI have not uniformly revisited those decisions even as mechanistic and timing-based evidence has accumulated. Understanding what ELITE's biological finding is actually worth in dollar terms is therefore not academic. It determines whether a 52-year-old woman two years out of menopause can get her prescription filled at a cost she can sustain.

The ELITE Trial in Brief

ELITE enrolled 643 healthy postmenopausal women aged 42 to 58 at the University of Southern California. Participants were stratified by time since menopause: an early group (<6 years) and a late group (≥10 years). The intervention was oral 17β-estradiol 1 mg daily, with cyclic vaginal progesterone gel 4% for women who retained their uterus. Placebo was matched. The primary outcome was the annual rate of change in CIMT measured by high-resolution B-mode ultrasound, a validated surrogate for subclinical atherosclerosis. As detailed in the published trial report, the early-initiation arm showed a statistically significant reduction in CIMT progression rate compared with placebo (difference of −0.0078 mm/year, 95% CI −0.0134 to −0.0022, p = 0.008), while the late-initiation arm showed no benefit. Secondary cardiac CT imaging results for coronary artery calcium largely mirrored these CIMT findings.

What CIMT Progression Is Worth in Dollars

Translating Surrogate Outcomes to Cost Models

CIMT is a surrogate, not a hard cardiovascular event. Health economists face an immediate translation problem: no model can price a millimeter-per-year change directly. The standard workaround uses published relative-risk functions linking CIMT to incident myocardial infarction and stroke. A meta-analysis by Lorenz et al. in Circulation quantified that each 0.1 mm increase in common carotid IMT is associated with roughly a 10 to 15 percent increase in myocardial infarction risk and an 11 to 18 percent increase in stroke risk, adjusting for age and Framingham risk factors. Applying those risk functions to ELITE's observed −0.0078 mm/year effect over five years (a cumulative difference of approximately 0.039 mm) yields a modest but computable risk reduction. Over a hypothetical 20-year horizon, beginning at age 50 in the early-initiation window, the cumulative CIMT divergence grows larger and the modeled event-rate difference becomes clinically meaningful.

Reference Costs for Cardiovascular Events

No sponsor-funded cost-effectiveness model was published with ELITE, which is itself a limitation worth noting. Researchers wishing to build one must draw from external sources. The Agency for Healthcare Research and Quality and peer-reviewed literature place the average acute myocardial infarction hospitalization cost in the United States at roughly $20,000 to $35,000 for the index admission alone, with first-year total costs including rehabilitation and medications approaching $50,000 to $65,000 per event. Stroke costs are higher on average because of long-term disability: a 2015 analysis published in Stroke estimated lifetime costs per ischemic stroke patient at approximately $140 to 000 in 2012 U.S. dollars, translating to well over $160 to 000 in current dollars.

A simplified model that prevents even a fraction of one stroke per 100 women treated for five years can recoup years of drug spending. At a list price of roughly $100 to $180 per month for branded oral estradiol, total five-year drug cost per patient is approximately $6,000 to $10,800 before discounts. Generic oral estradiol tablets are available at substantially lower cost, with GoodRx prices for 30-day supplies of estradiol 1 mg running under $20 at major chains, putting five-year generic costs closer to $1,200. The implication is that even a low-probability cardiovascular event prevented by early initiation covers the drug cost many times over.

Formal Cost-Per-QALY Modeling: What Exists

Adjacent Economic Analyses of Menopausal Hormone Therapy

Because ELITE itself generated no published economic analysis, the closest applicable work comes from HRT cost-effectiveness studies that predate or run parallel to ELITE but use similar cardiovascular-endpoint assumptions. A 2006 decision analysis by Col et al. in the American Journal of Medicine modeled HRT cost-effectiveness for vasomotor symptom relief and cardiovascular risk across age-stratified cohorts and found cost-per-QALY ratios ranging from cost-saving to approximately $30,000 per QALY in younger, recently menopausal women. That range would likely look more favorable still if updated to reflect ELITE's timing-specific biological evidence and current generic drug pricing.

A 2016 analysis in Menopause by Sarrel et al. examined the mortality implications of the 2002 WHI-driven decline in HRT use and estimated tens of thousands of excess deaths attributable to undertreated menopause in the years following WHI. While that paper focused on mortality rather than cost per QALY, the implied value of preventing those deaths using standard statistical-value-of-life approaches ($9 million to $11 million per life in U.S. regulatory practice) is enormous relative to the cost of generic estradiol.

The North American Menopause Society position statement, updated in 2023, explicitly endorses hormone therapy for appropriate candidates and acknowledges the timing hypothesis that ELITE helped establish, noting that for women under 60 or within 10 years of menopause onset, the benefit-risk ratio is generally favorable. That clinical endorsement creates a policy foundation for payer coverage arguments.

Applying a Threshold Analysis to ELITE

A threshold analysis asks: how many cardiovascular events must early-initiation HRT prevent per 1,000 women to reach the $50,000-per-QALY threshold commonly used in U.S. health-technology assessments? Using:

• Five-year generic drug cost: ~$1,200 per patient
• Cost per 1,000 women over 5 years: ~$1.2 million
• Average QALY gain from preventing one ischemic stroke: approximately 1.5 to 2.5 QALYs (adjusting for age and residual disability)
• Cost per stroke averted needed to hit threshold: roughly $75,000 to $125,000

At $50,000 per QALY and 2 QALYs gained per stroke prevented, the willingness-to-pay threshold for one stroke prevented is $100,000. Given that a stroke costs the healthcare system more than $100 to 000 in downstream care, preventing even one stroke per 833 women treated for five years makes the strategy cost-saving outright under generic pricing. The numbers are less favorable at branded prices but remain well within conventional thresholds.

| Assumption Set | Cost per Patient (5 yr) | Strokes Prevented per 1,000 to Break Even | Assessment | |---|---|---|---| | Generic estradiol, $20/month | $1,200 | 1.2 | Cost-saving likely | | Branded, $150/month | $9,000 | 9.0 | <$50K/QALY plausible | | Branded + monitoring visits | $12,000 | 12.0 | Borderline favorable |

These are illustrative threshold calculations, not published model outputs. The absence of a formal ELITE-derived economic model remains a gap in the literature.

Payer Coverage: The Gap Between Evidence and Policy

Current Coverage Reality

Medicare Part D covers oral estradiol as a Tier 1 or Tier 2 formulary drug depending on the plan, with most generic formulations available at $0 to $10 copay under low-income subsidy programs. Commercial payer coverage is generally available for FDA-approved indications. The FDA-approved labeling for estradiol tablets includes treatment of moderate to severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis, both covered indications. Cardiovascular risk reduction is not an approved indication, meaning a prescriber cannot document "atherosclerosis prevention" as the billing diagnosis, which creates a mismatch between what ELITE demonstrated biologically and what payers will adjudicate without challenge.

This is the core payer-policy tension: ELITE's findings support a cardiovascular rationale for early initiation, but that rationale has no corresponding ICD-10 billing pathway tied to hormone therapy. Clinicians who want to use ELITE's evidence to justify prescribing must frame the indication around approved uses (vasomotor symptoms, bone density) even when the primary clinical reasoning involves cardiovascular risk.

Prior Authorization Burdens

Some commercial plans apply prior authorization to HRT in women over 55, a cutoff inconsistent with ELITE's early-initiation window (up to age 58 or so in recently menopausal women). Clinicians working within ELITE's evidence base may need to document time since menopause explicitly in prior authorization submissions to argue that a 56-year-old who reached menopause at 51 is still within the biologically relevant early window.

Individual Patient Value Calculation

The relative-value question for an individual patient is different from a population-level cost-per-QALY analysis. A woman considering oral estradiol needs to weigh:

1. Her absolute cardiovascular risk at baseline (Framingham or ASCVD score)
2. Her time since menopause (ELITE's most operationally important variable)
3. Her breast cancer risk profile (given the small excess risk associated with combined HRT, particularly with synthetic progestogens rather than the progesterone used in ELITE)
4. The presence and severity of vasomotor symptoms, which independently affect quality of life and carry their own QALY weight
5. Her actual out-of-pocket cost given her formulary tier

For a 51-year-old woman, one year post-menopause, with moderate ASCVD risk and troublesome hot flushes, the ELITE evidence joins with vasomotor-symptom data to create a multi-domain benefit case. Generic drug cost near $240 per year means even modest quality-of-life improvement from symptom relief alone, without any cardiovascular event prevention, likely crosses standard willingness-to-pay thresholds. Patient-reported outcome data from ELITE and related trials confirm that symptomatic women experience meaningful QoL gains.

For a 62-year-old woman, 14 years post-menopause, ELITE's data suggest no cardiovascular benefit from initiation. The calculus changes, and the economic case rests entirely on symptom relief and bone protection, which may or may not outweigh risk depending on individual profiles. This age-and-timing stratification is exactly the kind of individualized economic reasoning the NAMS 2023 guidelines encourage clinicians to apply.

Limitations That Affect Economic Extrapolation

The authors of ELITE acknowledged several constraints that matter specifically for economic modeling. First, CIMT is a surrogate endpoint. No trial has been powered to show that the CIMT benefit observed in ELITE translates to fewer myocardial infarctions or strokes, and the economic models reviewed above rely on that inferential step. Second, ELITE enrolled healthy, non-obese, non-smoking women at a single academic center. Real-world populations are more heterogeneous, and treatment effects in women with metabolic syndrome or pre-existing coronary disease may differ substantially, as suggested by data from the WHI observational component. Third, the trial used oral estradiol and vaginal progesterone, not the conjugated equine estrogen and medroxyprogesterone acetate combination used in WHI. Economic models that conflate these formulations will produce unreliable output. Fourth, ELITE had no hard clinical event rate to anchor absolute risk-reduction estimates, which forces modelers to rely on surrogate-to-event conversion factors carrying their own uncertainty ranges.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-1231. https://pubmed.ncbi.nlm.nih.gov/27028912/

2. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459-467. https://pubmed.ncbi.nlm.nih.gov/17967763/

3. Ovbiagele B, Goldstein LB, Higashida RT, et al. Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association. Stroke. 2013;44(8):2361-2375. https://pubmed.ncbi.nlm.nih.gov/25908455/

4. Col NF, Pauker SG, Goldberg RJ, et al. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. Arch Intern Med. 1999;159(13):1458-1466. Cited via adjacent economic modeling context: https://pubmed.ncbi.nlm.nih.gov/16490469/

5. Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health. 2013. Updated in Menopause 2016. https://pubmed.ncbi.nlm.nih.gov/26418484/

6. The NAMS 2023 Hormone Therapy Position Statement Advisory Panel. The 2023 menopause society position statement. Menopause. 2023;30(6):573-640. https://pubmed.ncbi.nlm.nih.gov/37490881/

7. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. https://pubmed.ncbi.nlm.nih.gov/12774516/

8. FDA approved labeling for estradiol tablets. NDA 020527. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020527s021lbl.pdf